Science Reveals That This Type of Diet Can Increase Your Risk of Pancreatic Cancer
By MICHIGAN MEDICINE - UNIVERSITY OF MICHIGAN
According to a new study,
substances that are said to boost athletic performance can also activate a
receptor that speeds up the development of pancreatic cancer in mice.
The progression of
precancerous pancreatic lesions into pancreatic cancer is fueled by a cell
nuclear receptor that is activated by high-fat diets and synthetic compounds
found in unregulated sports performance enhancers, according to research from
the University of Michigan Rogel
Cancer Center.
Strategies to prevent
and treat pancreatic ductal adenocarcinoma, a particularly fatal type of cancer
with an increasing incidence, are urgently required. About 55 to 80 percent of
individuals over 40 are thought to have these low-grade pre-cancerous silent
pancreatic lesions, which are the primary cause of the majority of occurrences
of pancreatic cancer.
Pre-cancerous pancreatic
lesions in mice that are similar to those found in people contained greater
levels of the transcriptional receptor peroxisome proliferator-activated
receptor-delta (PPARδ), according to research conducted by Imad Shureiqi, M.D.
The research was published in the journal Nature Communications.
PPARδ controls the
expression of several important genes that affect biological processes
including lipid metabolism and the development of cancer. Pancreatic cancer
develops from precancerous lesions much more quickly when PPARδ is activated.
Prior to shifting his research to the cancer center in 2020, Shureiqi worked at
the University of Texas’ MD
Anderson Cancer Center where he completed the majority of this study,
specifically in collaboration with Xiangsheng Zuo, M.D., Ph.D.
“We became interested in
studying the effects of PPARδ on pancreatic carcinogenesis because our prior
observations showed that PPARδ strongly promoted other gastrointestinal
cancers. But there’s very limited information about PPARδ’s role in pancreatic
cancer’s development,” said Shureiqi.
Activation of PPARδ correlates with excessive exposure to certain ligands, both natural and synthetic. Some ligands naturally occur in high-fat diets, which have been associated with increased risk for pancreatic cancer in humans and animal models. High-fat diets are enriched with fatty acids that are natural ligands of PPARδ.
Other synthetic forms of
PPARδ ligands, like Cardarine (GW501516), are found in exercise supplements,
aimed to boost physical performance and endurance. GW501516 was originally
designed by pharmaceutical companies to encourage the body to use more fat and
treat noncancerous conditions like obesity and hyperlipemia.
The pharmaceutical
development of GW501516 and other similar potent PPARδ agonists for medical use
has long been discontinued given their potential procancerous side effects. Though
studies on how PPARδ affects colorectal cancer date back to 1999, and
pharmaceutical companies have halted synthetic PPARδ ligand development,
unregulated internet outlets still sell substances like Cardarine. Ads are
largely marketed to young people, claiming it will help them build muscle
endurance and burn fat.
Shureiqi explains that,
initially, researchers found that these synthetic ligands reduced fatigue in
mice. This news made its way to major media outlets, who nicknamed it “exercise
in a pill.” “Unfortunately, what the media didn’t address was the dark side of
PPARδ. Like muscle cells, synthetic PPARδ ligands also help cancer cells get
more energy from fats as a fuel source,” he said.
“It’s shocking to me,”
Shureiqi continued. “Animal models repeatedly show the strong relationship
between PPARδ and cancer promotion in the case of colorectal cancer and stomach
cancer. Now we’re gaining more information about how it affects pancreatic
cancer.”
Critical factors that
promote the progression of silent pancreatic precancerous lesions to pancreatic
cancer remain poorly defined, especially those that are easy to target. While
most of these pre-cancerous lesions don’t develop into cancer, understanding
how they progress is still crucial to finding interventions to address the
rising rate of pancreatic cancer. Findings from this study indicate that people
who have silent precancerous lesions, even those that are low grade, could
increase their risk of developing pancreatic cancer by consuming PPARδ natural activators,
like in high-fat diets, or synthetic ones, like Cardarine.
Future development of
effective agents to block PPARδ activation could be a new approach to prevent
the progression of precancerous lesions into pancreatic cancer. Limiting
exposure to high-fat diets could also be considered for those with a high
prevalence of pre-cancerous pancreatic lesions. But for now, the prevalent
sales and use of those athletic boosting synthetic PPARδ activating substances
cause the most pressing concern.
“This new information
should alert individuals to the potential serious health risks from using
synthetic PPARδ agonists,” Shureiqi said. “We’re trying to spread the message
that using those substances is not a good idea. It might enhance muscle
endurance, but it also enhances cancer’s ability to use energy and grow.”
Reference: “Rapid acceleration of KRAS-mutant
pancreatic carcinogenesis via remodeling of tumor immune microenvironment by
PPARδ” by Yi Liu, Yasunori Deguchi, Daoyan Wei, Fuyao Liu, Micheline J. Moussalli,
Eriko Deguchi, Donghui Li, Huamin Wang, Lovie Ann Valentin, Jennifer K. Colby,
Jing Wang, Xiaofeng Zheng, Haoqiang Ying, Mihai Gagea, Baoan Ji, Jiaqi Shi,
James C. Yao, Xiangsheng Zuo, and Imad Shureiqi, 13 May 2022, Nature
Communications.
DOI:
10.1038/s41467-022-30392-7
The study was funded by the NIH/National Cancer
Institute, the Cancer Prevention and Research Institute of Texas, the DDC seed
fund, the Cancer Center Support, and the CPRIT Core Facility Support.
